



The TIMI Trials

TIMI 5

OBJECTIVE: To evaluate the safety and efficacy of several doses of hirudin vs. unfractionated heparin in combination with front-loaded tPA for the treatment of patients presenting with ST elevation myocardial infarction.

1. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. *J Am Coll Cardiol* 1994;23:993-1003.
2. Loscalzo J, Abdenschein D, Eisenberg P, Becker R, George D, McCabe C, Sobel B, Braunwald E, for the TIMI 5 Investigators. Comparative effects of heparin and hirudin on fibrinolytic and thrombotic activities during tissue type plasminogen activator therapy. *Circulation* 1993;88.
3. Sharaf BL, Miele N, Ferreira P, McKendall GR, Williams DO. Culprit lesion changes in acute myocardial infarction: a TIMI 5 comparison of patients treated with t-PA and either heparin or hirudin. *J Am Coll Cardiol* 1993;21:419A.
4. Wackers FJT, Cannon CP, McMahon M, Zaret BL, and TIMI Investigators. Natural history of serial intrahospital quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction. *J Am Coll Cardiol* 1993;21 (Suppl. A):249A.
5. Cannon CP, Becker RC, Loscalzo J, Gallo P, Henis M, Edwards SJ, McCabe CH, Braunwald E, for the TIMI 5 Investigators. Usefulness of APTT to predict bleeding for hirudin (and heparin). *Circulation* 1994;90[Pt. 2]:I-563.
3. Boisjolie CR, Sharkey SW, Cannon CP, Brunette D, Haugland JM, Thatcher JL, Henry TD. Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department. *Am J Cardiol* 1995;76:396-8.
4. Becker RC, Cannon CP, George D, Loscalzo J, for the TIMI 5 Investigators. Toward establishing anticoagulation guidelines for intravenous heparin administration among patients with myocardial infarction given tissue plasminogen activator. *J Am Coll Cardiol* 1995;Special Issue:309A.
5. Henry TD, Becker RC, Cannon CP, McCabe CH, Loscalzo J, for the TIMI 5 Investigators. Is there a circadian variation in anticoagulant response to hirudin following acute myocardial infarction? *J Am Coll Cardiol* 1995;Special issue:310A.
6. Scharfstein JS, Abdenschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo J. Usefulness of fibrinolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. *Thrombolysis in Myocardial Infarction. Am J Cardiol* 1996;78:503-10.
6. Becker RC, Cannon CP, Ma Y, Hurley T, Hebert J. A composite and practical view of standard coagulation monitoring in the identification of patients at risk for major hemorrhage. *J Am Coll Cardiol* 1996;27 (Suppl. A):81A-82A.
7. Becker RC, Hebert J, Hurley T, Ma Y, Cannon CP, for the TIMI 5 Hemostasis and Thrombosis Study Group. Early aPTT measurement are not a surrogate for in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulation. *J Am Coll Cardiol* 1996;27(Suppl. A):11A-12A.